Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI)
in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other
study goals are to explore two different dosing schedules of pancrelipase and to evaluate
pancrelipase in people who do not have symptoms of EPI.